

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	Release of Security Interest Recorded at Reel/Frame 4423/345

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
JPMorgan Chase Bank, N.A., as Administrative Agent		06/17/2011	National Banking Association: UNITED STATES

RECEIVING PARTY DATA

Name:	Endo Pharmaceuticals Inc.
Street Address:	100 Endo Boulevard
City:	Chadds Ford
State/Country:	PENNSYLVANIA
Postal Code:	19317
Entity Type:	CORPORATION: DELAWARE

PROPERTY NUMBERS Total: 39

Property Type	Number	Word Mark
Registration Number:	3133550	1
Serial Number:	77704279	BACKING YOU UP
Registration Number:	3315385	DISPATCH
Registration Number:	2004648	ENDO
Registration Number:	2921176	ENDO
Registration Number:	0324936	ENDO
Registration Number:	2189503	ENDO
Registration Number:	3075226	ENDO ENDO GENERIC PRODUCTS
Registration Number:	2267677	ENDO GENERIC PRODUCTS
Registration Number:	2317044	ENDO LABORATORIES
Registration Number:	1993892	ENDOCET
Registration Number:	2411389	ENDOCODONE
Registration Number:	1995948	ENDODAN
Registration Number:	0399421	HYCODAN

TRADEMARK

900196802

REEL: 004580 FRAME: 0419

CH \$990.00 3133550

Registration Number:	0612080	HYCOMINE
Registration Number:	1019802	HYCOTUSS
Registration Number:	3090840	MAKE THE 1 DOSE DECISION
Registration Number:	3090823	MAKE THE 1 DOSE DECISION
Registration Number:	0921439	MOBAN
Registration Number:	0808366	NARCAN
Registration Number:	1062047	NUBAIN
Registration Number:	1936442	NUMORPHAN
Registration Number:	3060635	OPANA
Registration Number:	3585918	OPANA
Registration Number:	3252736	OPANA
Registration Number:	3553676	OPANA
Registration Number:	2946550	PAIN HAS MET ITS PATCH
Registration Number:	3314920	PARTNERSHIP FOR RESPONSIBLE OPIOID MANAGEMENT THROUGH INFORMATION, SUPPORT AND EDUCATION
Registration Number:	1051682	PERCOCET
Registration Number:	0507983	PERCODAN
Registration Number:	3265578	PROMISE
Registration Number:	3223709	PROMISE
Registration Number:	3223710	PROMISE
Registration Number:	0971190	SYMMETREL
Registration Number:	0778424	SYMMETREL
Registration Number:	3155766	TEAM ENDO
Registration Number:	3093722	THE SINGLE SHOT SOLUTION
Registration Number:	3015860	TREVOLON
Registration Number:	1412979	ZYDONE

CORRESPONDENCE DATA

Fax Number: (214)981-3400
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
Phone: 214-981-3483
Email: dclark@sidley.com
Correspondent Name: Dusan Clark, Esq.
Address Line 1: Sidley Austin LLP
Address Line 2: 717 N. Harwood St., Suite 3400
Address Line 4: Dallas, TEXAS 75201

ATTORNEY DOCKET NUMBER: 36084-36730

	Dusan Clark
Signature:	/Dusan Clark/
Date:	07/12/2011
Total Attachments: 4 source=JPM_ Endo Executed Release (EPI Trademarks)#page1.tif source=JPM_ Endo Executed Release (EPI Trademarks)#page2.tif source=JPM_ Endo Executed Release (EPI Trademarks)#page3.tif source=JPM_ Endo Executed Release (EPI Trademarks)#page4.tif	

RELEASE OF TRADEMARK SECURITY INTEREST

THIS RELEASE OF TRADEMARK SECURITY INTEREST is made effective as of June 17, 2011, by and from JPMORGAN CHASE BANK, N.A., for itself and as Administrative Agent for the Secured Parties (the "Administrative Agent") to ENDO PHARMACEUTICALS INC., a Delaware corporation (the "Grantor"), as follows:

WHEREAS, on November 30, 2010, the Grantor and the Administrative Agent entered into a Pledge and Security Agreement (the "Security Agreement") and a Confirmatory Grant of Security Interest in United States Trademarks (the "Confirmatory Grant");

WHEREAS, pursuant to the Security Agreement and the Confirmatory Grant, the Grantor pledged and granted to the Administrative Agent, on behalf of and for the benefit of the Secured Parties, among other collateral, a security interest in (1) all of the Grantor's right, title and interest in and to the trademarks (including service marks), trade names, trade styles, trade dress and the registrations and applications for registration thereof, including the Trademarks and the United States Trademarks listed on the attached Schedule A (the "Marks"), then owned or from time to time after the date thereof owned or acquired by the Grantor and the goodwill of the business symbolized by the foregoing; (2) all licenses of the foregoing, whether as licensee or licensor; (3) all renewals of the foregoing; (4) all income, royalties, damages, and payments now or hereafter due or payable with respect thereto, including, without limitation, damages, claims, and payments for past and future infringements thereof; and (5) all rights to sue for past, present, and future infringements of the foregoing, including the right to settle suits involving claims and demands for royalties owing;

WHEREAS, the Confirmatory Grant was recorded in the United States Patent & Trademark Office on December 1, 2010 at reel/frame 4423/345; and

WHEREAS, the Administrative Agent wishes to release its security interest in the all of the foregoing.

NOW THEREFORE, the Administrative Agent hereby releases the security interest in (1) all of the Grantor's right, title and interest in and to the trademarks (including service marks), trade names, trade styles, trade dress and the registrations and applications for registration thereof, including the Trademarks and the Marks listed on the attached Schedule A, now owned or from time to time after the date hereof owned or acquired by the Grantor and the goodwill of the business symbolized by the foregoing; (2) all licenses of the foregoing, whether as licensee or licensor; (3) all renewals of the foregoing; (4) all income, royalties, damages, and payments now or hereafter due or payable with respect thereto, including, without limitation, damages, claims, and payments for past and future infringements thereof; and (5) all rights to sue for past, present, and future infringements of the foregoing, including the right to settle suits involving claims and demands for royalties owing .and retransfers and reassigns any and all right, title and interest it may have in any of the foregoing without recourse to the Grantor.


Governing Law: THIS RELEASE OF TRADEMARK SECURITY INTEREST SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAW OF THE STATE OF NEW YORK.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, the Administrative Agent has caused this Release to be executed by its duly authorized officer.

JPMORGAN CHASE BANK, N.A.

By:



Name:

Deborah R. Winkler
Vice President

Title:

Schedule A
Security Interests in Trademarks recorded at
Reel 4423 Frame 345

Trademark	Country	App. No.	App. Date	Reg. No.	Reg. Date	Owner
1 & Design (Hand Logo)	United States	76/611,389	9/15/2004	3,133,550	8/22/2006	Endo Pharmaceuticals Inc.
ABANTRA	United States	77/957,541	3/12/2010			Endo Pharmaceuticals Inc.*
BACKING YOU UP	United States	77/704,279	4/1/2009			Endo Pharmaceuticals Inc.
CELFORGA	United States	77/787,742	7/23/2009			Endo Pharmaceuticals Inc.*
CENLOYA	United States	77/787,828	7/23/2009			Endo Pharmaceuticals Inc.*
CHRONOPATCH	United States	76/663,840	7/24/2006			Endo Pharmaceuticals Inc.*
DENLOYA	United States	77/787,803	7/23/2009			Endo Pharmaceuticals Inc.*
DISPATCH & Design	United States	76/671,163	1/8/2007	3,315,385	10/23/2007	Endo Pharmaceuticals Inc.
DOLESCA	United States	76/660,287	5/19/2006			Endo Pharmaceuticals Inc.*
ENDO	United States	74/464,554	12/1/1993	2,004,648	10/1/1996	Endo Pharmaceuticals Inc.
ENDO & Design	United States	76/453,299	9/25/2002	2,921,176	1/25/2005	Endo Pharmaceuticals Inc.
ENDO (Stylized #1)	United States	71/360,540	1/22/1935	0,324,936	6/4/1935	Endo Pharmaceuticals Inc.
ENDO (Stylized #2)	United States	75/431,737	2/10/1998	2,189,503	9/15/1998	Endo Pharmaceuticals Inc.
ENDO ENDO GENERIC PRODUCTS & Design	United States	76/607,520	8/18/2004	3,075,226	4/4/2006	Endo Pharmaceuticals Inc.
ENDO GENERIC PRODUCTS	United States	75/347,955	8/27/1997	2,267,677	8/3/1999	Endo Pharmaceuticals Inc.
ENDO LABORATORIES	United States	75/347,956	8/27/1997	2,317,044	2/8/2000	Endo Pharmaceuticals Inc.
ENDOCET	United States	74/519,259	4/22/1994	1,993,892	8/13/1996	Endo Pharmaceuticals Inc.
ENDOCODONE	United States	75/708,346	5/17/1999	2,411,389	12/5/2000	Endo Pharmaceuticals Inc.
ENDODAN	United States	74/519,256	4/22/1994	1,995,948	8/20/1996	Endo Pharmaceuticals Inc.
ENDOTUMORAL	United States	77/560,582	9/2/2008			Endo Pharmaceuticals Inc.*
FAZINYL	United States	76/660,285	5/19/2006			Endo Pharmaceuticals Inc.*
FORTESTA	United States	77/821,931	9/8/2009			Endo Pharmaceuticals Inc.*
FORTESTA (Testosterone Gel 2% CIII & Design)	United States	77/927,774	2/4/2010			Endo Pharmaceuticals Inc.*
HYCODAN	United States	71/455,017	8/21/1942	0,399,421	1/5/1983	Endo Pharmaceuticals Inc.
HYCOMINE	United States	71/667,025	5/25/1954	0,612,080	9/13/1995	Endo Pharmaceuticals Inc.
HYCOTUSS	United States	73/020,948	5/10/1974	1,019,802	9/9/1995	Endo Pharmaceuticals Inc.
IMUNASYNC	United States	77/787,886	7/27/2009			Endo Pharmaceuticals Inc.*
MAKE THE 1 DOSE DECISION	United States	76/629,294	1/25/2005	3,090,840	5/9/2006	Endo Pharmaceuticals Inc.
MAKE THE 1 DOSE DECISION & Design	United States	76/623,766	12/8/2004	3,090,823	5/9/2006	Endo Pharmaceuticals Inc.
MOBAN	United States	72/363,906	6/29/1970	921,439	10/5/1971	Endo Pharmaceuticals Inc.
MUNESYNC	United States	77/787,868	7/23/2009			Endo Pharmaceuticals Inc.*
NARCAN	United States	72/225,014	8/5/1965	808,366	5/17/1966	Endo Pharmaceuticals Inc.
NUBAIN	United States	73/082,855	4/5/1976	1,062,047	3/29/1977	Endo Pharmaceuticals Inc.
NUMORPHAN	United States	74/494,055	2/24/1994	1,936,442	11/21/1995	Endo Pharmaceuticals Inc.
OLINGA	United States	76/660,286	5/19/2006			Endo Pharmaceuticals Inc.*

(Endo Pharmaceuticals Inc.)

TRADEMARK
REEL: 004580 FRAME: 0424

Trademark	Country	App. No.	App. Date	Reg. No.	Reg. Date	Owner
OPANA	United States	76/478,457	12/20/2002	3,060,635	2/21/2006	Endo Pharmaceuticals Inc.
OPANA	United States	77/471,835	5/12/2008	3,585,918	3/10/2009	Endo Pharmaceuticals Inc.
OPANA & Design	United States	76/665,614	9/5/2006	3,252,736	6/19/2007	Endo Pharmaceuticals Inc.
OPANA & Design	United States	77/471,861	5/12/2008	3,553,676	12/30/2008	Endo Pharmaceuticals Inc.
OPRELIS	United States	77/957,558	3/12/2010			Endo Pharmaceuticals Inc.*
PAIN HAS MET ITS PATCH	United States	76/523,991	6/19/2003	2,946,550	5/3/2005	Endo Pharmaceuticals Inc.
PARTNERSHIP FOR RESPONSIBLE OPIOID MANAGEMENT THROUGH INFORMATION, SUPPORT AND EDUCATION	United States	76/664,475	8/11/2006	3,314,920	10/16/2007	Endo Pharmaceuticals Inc.
PERCOCET	United States	73/072,165	12/18/1975	1,051,682	11/2/1976	Endo Pharmaceuticals Inc.
PERCODAN	United States	71/553,092	3/26/1948	507,983	3/22/1949	Endo Pharmaceuticals Inc.
PROMISE	United States	76/648,085	10/3/2005	3,265,578	7/17/2007	Endo Pharmaceuticals Inc.
PROMISE	United States	76/663,844	7/24/2006	3,223,709	4/3/2007	Endo Pharmaceuticals Inc.
PROMISE & Design	United States	76/663,845	7/24/2006	3,223,710	4/3/2007	Endo Pharmaceuticals Inc.
RAPINYL	United States	77/605,946	11/3/2008			Endo Pharmaceuticals Inc.*
REVOPAN	United States	77/957,575	3/12/2010			Endo Pharmaceuticals Inc.*
SYMMETREL	United States	72/427,398	6/15/1973	971,190	10/23/1993	Endo Pharmaceuticals Inc.
SYMMETREL	United States	72/190,162	4/1/1964	778,424	10/13/1964	Endo Pharmaceuticals Inc.
SYMYCEP	United States	77/787,782	7/23/2009			Endo Pharmaceuticals Inc.*
TEAM ENDO	United States	76/639,353	5/24/2005	3,155,766	10/17/2006	Endo Pharmaceuticals Inc.
THE SINGLE SHOT SOLUTION	United States	76/611,388	9/15/2004	3,093,722	5/16/2006	Endo Pharmaceuticals Inc.
TREVOLON	United States	76/365,419	1/31/2002	3,015,860	11/15/2005	Endo Pharmaceuticals Inc.
TRF	United States	76/679,225	7/9/2007			Endo Pharmaceuticals Inc.*
VERLOTRA	United States	77/823,612	9/10/2009			Endo Pharmaceuticals Inc.*
ZELSTED	United States	77/787,757	7/23/2009			Endo Pharmaceuticals Inc.*
ZYDONE	United States	73/588,206	3/17/1986	1,412,979	10/14/1986	Endo Pharmaceuticals Inc.
VERSAVITA	United States	85/150796	10/12/2010			Endo Pharmaceuticals Inc.*
MEDLAUNCH	United States	85/150811	10/12/2010			Endo Pharmaceuticals Inc.*

*The trademarks containing an asterisk are or were intent-to-use applications and were not recorded with the USPTO. As such, they will not be recorded with the Release.

(Endo Pharmaceuticals Inc.)